Myriad Genetics Inc (MYGN) Stock Price & Analysis
Myriad Genetics Inc (MYGN) rose 3.42% to USD 4.54 as of June 10, 2026 at 03:35 UTC, according to Nexqual real-time market data.
MYGN last closed at USD 4.39; the session ranged USD 4.32–4.54 on volume of 1,137,926 shares. Market capitalization is $428.79M, with a 52-week range of USD 3.53–8.59 (NMS). Source: Nexqual, June 10, 2026 at 03:35 UTC.
Key Statistics (as of June 10, 2026 at 03:35 UTC)
| Price | USD 4.54 |
|---|---|
| Change | ▲ 3.42% (up) |
| Previous Close | USD 4.39 |
| Open | USD 4.42 |
| Day Range | USD 4.32 – 4.54 |
| 52-Week Range | USD 3.53 – 8.59 |
| Volume | 1,137,926 shares |
| Market Cap | $428.79M |
| Exchange | NMS |
Technical Analysis (MYGN)
Nexqual's technical model rates MYGN "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:35 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 53.89 (neutral) |
| vs SMA50 | Above (USD 4.44) |
| MACD | 0.04 (positive) |
Analyst Ratings (MYGN)
Wall Street analysts rate MYGN "Hold" based on 8 analysts, with a mean price target of USD 6.25 (range USD 4–10), per Nexqual as of June 10, 2026 at 03:35 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 6.25 |
| High Target | USD 10 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 2 / 5 / 2 |
Earnings (MYGN)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.06 |
| Revenue Estimate | $206.03M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.09 vs est -0.07 ▼ miss |
| 2025-12-31 | USD 0.04 vs est -0.02 ▲ beat |
| 2025-09-30 | USD 0 vs est -0.01 ▲ beat |
| 2025-06-30 | USD 0.05 vs est -0.01 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Financials & Fundamentals (MYGN)
| Total Revenue | $557.00M |
|---|---|
| Revenue Growth (YoY) | -20.80% |
| Gross Margin | +68.06% |
| Operating Margin | -21.41% |
| Profit Margin | -41.29% |
| ROE | -23.51% |
| Debt / Equity | 32.85 |
| Current Ratio | 2.67 |
| Total Cash | $150.70M |
| Total Debt | $0 |
| Free Cash Flow | $-46.06M |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Financial Health Score (MYGN)
Nexqual rates Myriad Genetics Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:35 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 68%, operating -21% |
| Balance Sheet | Strong — $151M cash, no debt |
| Cash Flow | Weak — FCF negative: -$46M, burning cash |
| Efficiency | Critical — ROE -24%, ROA -7.6% |
Ownership (MYGN)
| Insider Ownership | +3.77% |
|---|---|
| Institutional Ownership | +97.63% |
| Shares Outstanding | 94.45M |
| Float | 85.99M |
| Short % of Float | +9.28% |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Leadership (MYGN)
Myriad Genetics Inc is led by Samraat S. Raha (age 52), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:35 UTC.
| President, CEO & Director | Samraat S. Raha (age 52) |
|---|---|
| CFO & Principal Accounting Officer | Benjamin R. Wheeler (age 41) |
| Chief Operating Officer | Mark S. Verratti (age 57) |
| Chief Scientific Officer | Dale Muzzey (age 45) |
| Chief Technology Officer | Raj Jampa |
Major Backers & Investors (MYGN)
Notable institutional backers of Myriad Genetics Inc include Millennium Management, Glenview Capital Management, Llc, Shaw D.E. & Co., Inc., according to Nexqual as of June 10, 2026 at 03:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Millennium Management | 7.06% |
| Glenview Capital Management, Llc | 5.73% |
| Shaw D.E. & Co., Inc. | 4.76% |
| Morgan Stanley | 3.36% |
| Goldman Sachs | 2.51% |
| abrdn Healthcare Opportunities Fund | 1.18% |
| Federated Hermes MDT Series-Federated Hermes MDT Small Cap Core Fund | 1.06% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.21% |
| Vanguard Group | 11.86% |
| State Street | 7.17% |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
From Myriad Genetics Inc's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests.
- The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
- It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
- It has a license collaboration with Illumina, Inc.; University of Texas M.D.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INCY | Incyte Corporation | USD 103.23 | ▲ 0.83% |
| ALKS | Alkermes plc | USD 44.29 | ▲ 3.48% |
| NBIX | Neurocrine Biosciences, Inc. | USD 165.24 | ▲ 0.83% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 243.28 | ▲ 2.65% |
| UTHR | United Therapeutics Corporation | USD 553.14 | ▲ 0.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:35 UTC. This page is informational and not investment advice.